Clinical Trials Sponsored by Janssen Research & Development, LLC

Total 1110 results

Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
Janssen Research & Development, LLC

Completed

A Registry of Participants With Prostate Cancer in Asia

Prostatic Neoplasms

China, Taiwan, India, Malaysia, Japan, Korea, Republic of, Singapore, Thailand
Janssen Research & Development, LLC

Completed

A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
Janssen Research & Development, LLC

Completed

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Uterine Hemorrhage

United States
Janssen Research & Development, LLC

Completed

A Study of Ketamine in Patients With Treatment-resistant Depression

Major Depressive Disorder

United States
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Hepatitis C

Singapore, Canada, Poland, New Zealand
Janssen Research & Development, LLC

Completed

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Healthy

United States
Janssen Research & Development, LLC

Completed

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Poland, Germany, Spain, Mexico, Australia, Taiwan, Argentina, Hungary
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

Healthy

Belgium, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

Australia, France, United Kingdom, Belgium, Taiwan, United States, Spain, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sweden, Korea, Republic of, Canada, Netherlands, Brazil, Germany, Poland
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin (COMETA)

Diabetes Mellitus, Type 2

Mexico
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Ukraine, Taiwan, Poland, Korea, Republic of, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Stroke

United States
Janssen Research & Development, LLC

Completed

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
Janssen Research & Development, LLC

Completed

A Prospective Patient Registry of Patients Exposed to Bedaquiline

Pulmonary Multi-drug Resistant Tuberculosis

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder (DriveSaFe2)

Depressive Disorder, Major

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Prostate Cancer

Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Nonradiographic Axial Spondylitis, Ankylosing

Australia, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Poland, Korea, Republic of, Russian Federation, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Aneurysm, Dissecting | Retinal Detachment | Achilles Tendon

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

United States, Australia, France, Belgium, Turkey, Netherlands, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Breast Cancer | Neoplasm Metastasis

United States, Poland, Ukraine, Taiwan, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Hong Kong, Chile, Brazil, Philippines, Ecuador, Macedonia, The Former Yugoslav Republic... and more
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Terminated

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

Ankylosing Spondylitis

United States, Poland, Ukraine, Germany, Korea, Republic of, Russian Federation, Australia, Mexico, Canada
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

No longer available

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Sarcoma

United States, Canada, Israel
Janssen Research & Development, LLC

Completed

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

Pain | Osteoarthritis

United States, Spain, Poland, United Kingdom

3

Subscribe